Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease

Inclusion Criteria: * Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic, and histologic criteria) in clinical remission (SCCAI = 0) from at least three months and in stable therapy (without therapeutic modifications in the three previous months) with mesalazine, immunomodulators and/or biologics. * Patients affected by Crohn's Disease, particularly involving sigmoid colon and rectum (diagnosed on the base of clinic, endoscopic, and histologic criteria) in clinical remission (CDAI \< 150) from at least three months and in stable therapy (without therapeutic modifications in the three previous months) with mesalazine A, immunomodulators and/or biologics. * Fecal calprotectin at baseline ≥ 100 microg/g. * Signed informed consent. Exclusion Criteria: * Patients affected by Ulcerative Colitis and Crohn's Disease with severe endoscopic disease activity (Ulcerative Colitis: Mayo Endoscopic Score = 3; Crohn's Disease: Simple Endoscopic Score SES-CD \> 15). * Patients on steroid therapy in the two previous months. * Patients in therapy with warfarin or other anticoagulants. * Known or supposed hypersensitivity to fruit and/or juice of pomegranate. * Women in fertile age which refuse to use contraceptives specified in the study (oral contraception, IUD) and breastfeed women. * Diabetic patients and other patients with severe clinical conditions which the investigator consider to contraindicate patient participation at the study. * Therapy modifications an…